Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00217830 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A2 | EXPERIMENTAL | - |
| A5 | PLACEBO_COMPARATOR | - |
| A4 | ACTIVE_COMPARATOR | - |
| A3 | EXPERIMENTAL | - |
| A1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-00217830 | DRUG | PF-00217830 5 mg, oral capsule, once daily for 21 days |
| Placebo | OTHER | Placebo, oral capsule, once daily for 21 days |
| Aripiprazole | DRUG | Aripiprazole 15 mg, oral capsule, once daily for 21 days |
Inclusion Criteria: Key inclusion criteria include: * Have a current diagnosis of schizophrenia. * Increase in symptoms over the past 2-4 weeks. * Willing to remain inpatients for the duration of the trial. Exclusion Criteria: * Subjects with a current DSM-IV axis I diagnosis other than schizoph...
PF-00217830 is an investigational small molecule being studied for the treatment of schizophrenia. It was evaluated in a Phase 2 clinical trial for acute exacerbation of schizophrenia. The drug is not approved and remains in clinical development.
PF-00217830 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company sponsored the clinical trial of this investigational drug for schizophrenia.
PF-00217830 is in Phase 2 clinical development. It has completed one Phase 2 trial for schizophrenia, but it is not approved by regulatory authorities and remains investigational.
PF-00217830 has one completed Phase 2 clinical trial, identified as NCT00580125. This was a dose-response study evaluating the safety, efficacy, and pharmacokinetics of PF-00217830 compared with placebo in patients with acute exacerbation of schizophrenia.
Yes, PF-00217830 was tested in a randomized, double-blind, placebo-controlled Phase 2 trial. The study enrolled 164 participants with schizophrenia across the United States, India, Russia, and Ukraine, and it has been completed.